{"id":473980,"date":"2020-03-16T09:10:02","date_gmt":"2020-03-16T09:10:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=473980"},"modified":"2020-03-16T09:10:02","modified_gmt":"2020-03-16T09:10:02","slug":"hemophilia-a-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-market-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_473980.html","title":{"rendered":"Hemophilia A Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight"},"content":{"rendered":"
\"Hemophilia<\/a><\/p>\n
\n
hemophilia A market research<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

DelveInsight’s “<\/em> Hemophilia A<\/strong> Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the <\/em>Hemophilia A<\/strong>, historical and forecasted epidemiology as well as the <\/em>Hemophilia A<\/strong> market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/em><\/p>\n

 <\/p>\n

DelveInsight has launched a new report on Hemophilia A Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

 <\/p>\n

Hemophilia A is a general term for a group of rare bleeding disorders caused by a congenital deficiency of certain clotting factors. The main form of hemophilia is hemophilia A; it is different from Hemophilia B. The main difference between them is that Hemophilia B is associated with deficiency in factor IX (9) while Hemophilia A is associated with deficiency of factor VIII. More than 80% of people with hemophilia have hemophilia A.<\/p>\n

 <\/p>\n

Request for sample page: – <\/strong>Hemophilia A Sample Page Link<\/a><\/p>\n

 <\/p>\n

Hemophilia A Epidemiology  <\/strong><\/p>\n

The Hemophilia A<\/strong> epidemiology division provides insights about historical and current Hemophilia A <\/strong>patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. <\/p>\n

 <\/p>\n

Some of the Report Key facts:-<\/strong><\/p>\n

    \n
  1. The total prevalent population of Hemophilia A in the 7MM expected to rise by 2030, during the study period [2017–2030]. Total diagnosed and treated prevalent population of Hemophilia A in the 7MM was assessed to be 38,212 in 2017.<\/li>\n
  2. According to DelveInsight’s analysis, the highest prevalent population of Hemophilia A is in the United States with 14,200 cases in 2017.<\/li>\n
  3. In the 7MM, approximately 30% of severe hemophilia A cases, i.e., 6,305 patients affected by inhibitors. In addition to this, 70% of the Hemophilia A cases were observed without inhibitors in 2017.<\/li>\n<\/ol>\n

     <\/strong><\/p>\n

    Report Key Benefits<\/strong><\/p>\n

    1. Hemophilia A <\/strong> market report covers a descriptive overview and comprehensive insight of the Hemophilia A<\/strong> epidemiology Hemophilia A<\/strong> market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)<\/p>\n

    2. Hemophilia A<\/strong> market report provides insights on the current and emerging therapies.<\/p>\n

    3. Hemophilia A<\/strong> market report offers a global historical and forecasted market covering drug outreach in 7 MM.<\/p>\n

    4. Hemophilia A<\/strong> market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Hemophilia A<\/strong> market.<\/p>\n

     <\/p>\n

    “According to DelveInsight’s analysis, severe cases of Hemophilia A are more prominent in comparison to mild and moderate cases.”<\/strong><\/p>\n

     <\/p>\n

    Some of the key companies working on Hemophilia A that are given below-<\/strong><\/p>\n

      \n
    1. NOVO NORDISK Pharmaceutical Company<\/li>\n
    2. BAYER Pharmaceutical Corporation<\/li>\n
    3. GENENTECH Biotechnology Pharmaceutical Company<\/li>\n
    4. OCTAPHARMA Pharmaceutical Company<\/li>\n
    5. TAKEDA Pharmaceutical Company<\/li>\n
    6. SANOFI Pharmaceutical Company<\/li>\n<\/ol>\n

        Name of covered Drugs are given below.<\/strong><\/p>\n

        \n
      1. ESPEROCT<\/li>\n
      2. JIVI<\/li>\n
      3. HEMUBRA<\/li>\n
      4. WILATE<\/li>\n
      5. ADYNOVATE<\/li>\n
      6. ELOCTATE<\/li>\n<\/ol>\n

         <\/p>\n

        Table of Contents<\/a><\/p>\n

        1. Key Insights<\/em><\/p>\n

        2. Executive Summary of Hemophilia A<\/em><\/p>\n

        3. Competitive Intelligence Analysis for Hemophilia A<\/em><\/p>\n

        4. Hemophilia A: Market Overview at a Glance<\/em><\/p>\n

        5. Hemophilia A: Disease Background and Overview<\/em><\/p>\n

        6. Patient Journey<\/em><\/p>\n

        7. Hemophilia A Epidemiology and Patient Population<\/em><\/p>\n

        8. Treatment Algorithm, Current Treatment, and Medical Practices<\/em><\/p>\n

        9. Unmet Needs<\/em><\/p>\n

        10. Key Endpoints of Hemophilia A Treatment<\/em><\/p>\n

        11. Marketed Products<\/em><\/p>\n

        13. Hemophilia A: Seven Major Market Analysis<\/em><\/p>\n

        15. 7MM: Market Outlook<\/em><\/p>\n

        16. Access and Reimbursement Overview of Acute Hemophilia A<\/em><\/p>\n

        17. KOL Views<\/em><\/p>\n

        18. Market Drivers<\/em><\/p>\n

        19. Market Barriers<\/em><\/p>\n

        20. Appendix<\/em><\/p>\n

        20.1. Bibliography<\/em><\/p>\n

        20.2. Report Methodology<\/em><\/p>\n

        21. DelveInsight Capabilities<\/em><\/p>\n

        22. Disclaimer<\/em><\/p>\n

        23. About <\/em>DelveInsight<\/a><\/p>\n

        Why should you buy this Hemophilia A Report?<\/strong><\/p>\n